Allied Market Research recently published a research report on “Immune Checkpoint Inhibitors Market by Type, Application: Global Opportunity Analysis and Industry Forecast, 2021-2030,” the global immune checkpoint inhibitors market was valued at $29,803.71 million in 2020, and is projected to reach $1,40,890.10 million by 2030, registering a CAGR of 16.8% from 2021 to 2030.
Immune checkpoint inhibitors target checkpoint proteins and help the immune system recognize and attack cancer cells. Immune checkpoint inhibitors are expected to exhibit significant market growth over the forecast period due to increase in demand for ideal therapies for cancer treatment, favorable reimbursement policies provided by manufacturers and insurance providers in some countries, and increasing incidence of cancer worldwide.
𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭@ https://www.alliedmarketresearch.com/request-sample/3723
By application, the Immune checkpoint inhibitor market is classified as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, and others. The lung cancer segment currently dominates the market and is expected to remain dominant during the forecast period owing to the rise in the use of immune checkpoint inhibitors for the treatment of lung cancer and the rise in lung cancer globally.
The global immune checkpoint inhibitors market is segmented into CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, and others. The PD-1 inhibitor segment was the major revenue contributor in 2020 and is expected to continue this trend over the forecast period due to increased adoption of PD-1 inhibitors such as pembrolizumab and nivolumab globally.
North America accounted for more than 66.7% of the global immune checkpoint inhibitor market in 2020 and is expected to remain dominant throughout the forecast period. The increase in demand for immune checkpoint inhibitors, high prevalence of cancer, increase in the number of trained medical professionals and supportive reimbursement policies in the healthcare system are attributed to this.
𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐈𝐧𝐪𝐮𝐢𝐫𝐲@ https://www.alliedmarketresearch.com/purchase-enquiry/3723
𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬:
This report provides comprehensive competitive analysis and profiles of key players in the Immune Checkpoint Inhibitor market such as AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences.) GlaxoSmithKline Plc, F. Hoffmann-La Rochenche. Ltd. Inc., Sanofi, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), and BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd.
𝐎𝐭𝐡𝐞𝐫 𝐓𝐫𝐞𝐧𝐝𝐢𝐧𝐠 𝐑𝐞𝐩𝐨𝐫𝐭𝐬:
Culture Media Market
𝐀𝐯𝐞𝐧𝐮𝐞 𝐁𝐚𝐬𝐢𝐜 𝐏𝐥𝐚𝐧 | 𝐋𝐢𝐛𝐫𝐚𝐫𝐲 𝐀𝐜𝐜𝐞𝐬𝐬 | 𝟏 𝐘𝐞𝐚𝐫 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐩𝐭𝐢𝐨𝐧 |
Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.
Request for 14 days free trial: https://www.alliedmarketresearch.com/avenue/trial/starter
𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.